Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 16/20 | 0.53 |
| ▸ | PGR | P06401 | 2/20 | 0.41 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7056620 | 0.80 | AR (0.47) | ARPGR | |
| SCHEMBL5789282 | 0.80 | CYP3A4 (0.48) | AR | |
| SCHEMBL8996023 | 0.78 | CXCR1 (0.43) | AR | |
| SCHEMBL13106347 | 0.78 | AR (0.51) | ARPGRNR3C2 | |
| SCHEMBL29863815 | 0.78 | AR (0.51) | ARPGRNR3C2 | |
| SCHEMBL3976812 | 0.78 | AR (0.51) | ARPGRNR3C2 | |
| SCHEMBL10742861 | 0.75 | AR (0.40) | ARPGR | |
| SCHEMBL974487 | 0.75 | AR (0.49) | ARPGRNR3C2NR3C1 | |
| SCHEMBL973688 | 0.75 | AR (0.49) | ARPGRNR3C2NR3C1 | |
| SCHEMBL998935 | 0.75 | AR (0.38) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022212296-A1 | ARYL HETEROCYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D.E. SHAW RESEARCH, LLC (US) | 2022-10-06 | — | — | WO | disclosed |
| WO-2021071802-A1 | ARYL HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC (US) | 2021-04-15 | — | — | WO | disclosed |
| US-7956070-B2 | Piperidines as chemokine modulators (CCR) | ASTRAZENECA AB (SE) | 2011-06-07 | — | — | US | disclosed |
| US-20070054924-A1 | Novel piperidines as chemokine modulators (ccr) | ASTRAZENECA AB (SE) | 2007-03-08 | — | — | US | disclosed |
| EP-1713772-A1 | NOVEL PIPERIDINES AS CHEMOKINE MODULATORS (CCR) | AstraZeneca AB (SE) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005073192-A1 | NOVEL PIPERIDINES AS CHEMOKINE MODULATORS (CCR) | ASTRAZENECA AB (SE) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054924-A1 | Novel piperidines as chemokine modulators (ccr) | CCR3, CCR1, CCR4 | AR 1959/4885PGR 2208/4885NR3C2 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.